<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Management of stable angina.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Clinical Guideline Centre. Management of stable angina. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Jul. 34 p.&amp;nbsp;(Clinical guideline; no. 126).&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Aortocoronary bypass for heart revascularization, not otherwise specified  (36.10); Other and unspecified angina pectoris  (413.9)"/><FieldValue Value="MSH: Acetanilides ; Adrenergic beta-Antagonists ; Angina Pectoris ; Angina, Stable ; Angioplasty, Balloon, Coronary ; Angiotensin-Converting Enzyme Inhibitors ; Aspirin ; Benzazepines ; Coronary Artery Bypass ; Diagnosis ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Life Style ; Myocardial Revascularization ; Nicorandil ; Nitrates ; Patient Education as Topic ; Percutaneous Coronary Intervention ; Piperazines "/><FieldValue Value="MTH: Adrenergic beta-Antagonists ; Angina Pectoris ; Angioplasty, Balloon, Coronary ; Angiotensin-Converting Enzyme Inhibitors ; Aspirin ; Coronary Artery Bypass Surgery ; Diagnosis ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Life Style ; Nitrates ; Patient education (procedure) ; Percutaneous Coronary Intervention ; Stable angina "/><FieldValue Value="PDQ: acetylsalicyclic acid "/><FieldValue Value="SNOMEDCT_US: Angina pectoris  (194828000); Angina pectoris  (225566008); Angiotensin-converting enzyme inhibitor agent  (372733002); Angiotensin-converting enzyme inhibitor agent  (41549009); Antianginal therapy  (308117007); Aspirin  (387458008); Aspirin  (7947003); Benzazepine  (413639003); beta-Blocking agent  (33252009); beta-Blocking agent  (373254001); Coronary artery bypass graft  (232717009); Coronary artery bypass graft  (67166004); Coronary artery bypass graft  (90205004); Diagnosis  (439401001); HMG-CoA reductase inhibitor  (372912004); HMG-CoA reductase inhibitor  (96302009); Ivabradine  (421228002); Ivabradine  (421692002); Life style  (134436002); Life style  (60134006); Myocardial revascularization  (174911007); Myocardial revascularization  (275227003); Myocardial revascularization  (81266008); Nicorandil  (319304004); Nicorandil  (395809002); Nitrate salt  (89119000); Patient education  (311401005); Percutaneous coronary intervention  (415070008); Ranolazine  (420365007); Ranolazine  (420624001); Stable angina  (233819005)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Stable angina&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Diagnosis" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Preventive Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Hospitals" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To offer best practice advice on the care of people with stable angina&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adults (18 years and older) who have been diagnosed with stable angina due to atherosclerotic disease, including:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;People of south Asian origin &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;People older than 85 years &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;People with chronic refractory angina &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;People with diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;People with normal or minimally diseased coronary arteries &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Women &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Groups that are not covered in the guideline include people with recent-onset chest pain or discomfort of suspected cardiac origin, people with acute coronary syndrome, people with chest pain or discomfort of unknown cause, people with angina-type pain that is likely to be due to non-cardiac disease, such as anaemia, people with angina-type pain associated with other types of heart disease, such as valvular heart disease (for example, aortic stenosis) or cardiomyopathy (for example, hypertrophic cardiomyopathy).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Accurate diagnosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lifestyle advice and patient education &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Preventing and treating episodes of angina: short-acting nitrate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Drugs for secondary preventions&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Aspirin &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Angiotensin-converting enzyme (ACE) inhibitors &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Statins &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Anti-anginal drug treatment&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Beta-blocker or calcium channel blocker &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;If indicated: long-acting nitrate, ivabradine, nicorandil, ranolazine &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Revascularisation surgery for those not controlled on optimal medical management&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Coronary artery bypass graft &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Percutaneous coronary intervention &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Outcomes in Intervention Studies&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Exercise tolerance &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nitroglycerin consumption &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Angina frequency/severity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Myocardial infarction (MI)/non-fatal MI &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Revascularisation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hospitalisation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stroke/cerebrovascular accident &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Death &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cardiac/cardiovascular death &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse events &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Outcomes in Prognostic Studies&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Death &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cardiac death/cardiovascular death &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;MI/Nonfatal MI &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Revascularisation &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC)&lt;/strong&gt;: This guideline was developed by the National Clinical Guideline Centre on behalf of the National Institute for Health and Clinical Excellence (NICE). See the &quot;Availability of Companion Documents&quot; field for the full version of this guidance.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Clinical Literature Search&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Systematic literature searches were undertaken to identify evidence within published literature in order to answer the review questions as per The NICE Guidelines Manual. Clinical databases were searched using relevant medical subject headings, free-text terms and study type filters where appropriate. Non-English studies were not reviewed and were therefore excluded from searches. All searches were conducted on core databases, Medline, EMBASE, CINAHL and The Cochrane Library. Additional subject specific databases were used for some questions. All searches were updated on the 22nd of October 2010. No papers after this date were considered.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Search strategies were checked by looking at reference lists of relevant key papers, checking search strategies in other systematic reviews and asking the Guideline Development Group (GDG) for known studies. The questions, the study types applied, the databases searched and the years covered can be found in Appendix D of the full version of the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;During the scoping stage, a search was conducted for guidelines and reports on the websites listed below and on organisations relevant to the topic. Searching for grey literature or unpublished literature was not systematically performed. All references sent by stakeholders were considered.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Constituent websites of the Guidelines International Network (&lt;a href=&quot;http://www.g-i-n.net&quot; title=&quot;Guidelines International Network web site&quot;&gt;www.g-i-n.net&lt;/a&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National Guideline Clearinghouse (&lt;a href=&quot;http://www.guideline.gov/&quot; title=&quot;NGC web site&quot; target=&quot;_blank&quot;&gt;www.guideline.gov/&lt;/a&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National Institute for Health and Clinical Excellence (NICE) (&lt;a href=&quot;http://www.nice.org.uk&quot; title=&quot;NICE web site&quot;&gt;www.nice.org.uk&lt;/a&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National Institutes of Health Consensus Development Program (&lt;a href=&quot;http://www.consensus.nih.gov&quot; title=&quot;NIH Consensus Development Program web site&quot; target=&quot;_blank&quot;&gt;consensus.nih.gov/&lt;/a&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National Library for Health (&lt;a href=&quot;http://www.library.nhs.uk/&quot; title=&quot;National Library for Health web site&quot;&gt;www.library.nhs.uk/&lt;/a&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Health Economic Literature Search&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Systematic literature searches were also undertaken to identify health economic evidence within published literature relevant to the review questions. The evidence was identified by conducting a broad search relating to the stable angina population in the National Health Service (NHS) Economic Evaluation Database (NHS EED), the Health Economic Evaluations Database (HEED) and Health Technology Assessment (HTA) databases with no date restrictions up to 13/9/10. Additionally, the search was run on Medline (years 1950&amp;ndash;2007) and EMBASE (1996&amp;ndash;2007), with a specific economic filter, to ensure recent publications that had not yet been indexed by these databases were identified. This was supplemented by additional searches from (1990&amp;ndash;13/9/10) that looked for economic papers specifically relating to revascularisation, rehabilitation, nicorandil, long-acting nitrates on Medline, EMBASE, Cochrane (technology assessments [TAs] and economic evaluations&amp;nbsp;[EEs]), as it became apparent that some papers in this area were not being identified through the first search.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The search strategies for health economics are included in Appendix D of the full version of the original guideline document. All searches were updated on the 13th Sept 2010. No papers after this date were considered.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Reviewing the Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Research Fellow and Health Economist:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Identified potentially relevant studies for each review question from the relevant search results by reviewing titles and abstracts &amp;ndash; full papers were then obtained &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reviewed full papers against pre-specified inclusion/exclusion criteria to identify studies that addressed the review question in the appropriate population and reported on outcomes of interest (research protocols are included in Appendix C of the full version of the original guideline document) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Overall Quality of Outcome Evidence in Grading of Recommendations Assessment, Development and Evaluation (GRADE)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;High&lt;/strong&gt;: Further research is &lt;em&gt;very unlikely&lt;/em&gt; to change the confidence in the estimate of effect&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Moderate&lt;/strong&gt;: Further research is &lt;em&gt;likely&lt;/em&gt; to have an important impact on the confidence in the estimate of effect and may change the estimate&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Low&lt;/strong&gt;: Further research is &lt;em&gt;very likely&lt;/em&gt; to have an important impact on the confidence in the estimate of effect and is likely to change the estimate&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Very low&lt;/strong&gt;: Any estimate of effect is &lt;em&gt;very uncertain&lt;/em&gt;&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Meta-Analysis" /><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review with Evidence Tables" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC)&lt;/strong&gt;:This guideline was developed by the National Clinical Guideline Centre on behalf of the National Institute for Health and Clinical Excellence (NICE). See the &quot;Availability of Companion Documents&quot; field for the full version of this guidance.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Reviewing the Evidence&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Research Fellow and Health Economist:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Critically appraised relevant studies using the appropriate checklist as specified in The Guidelines Manual &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Extracted key information about the study's methods and results into evidence tables (evidence tables are included in Appendix E2 in the full version of the original guideline) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Generated summaries of the evidence by outcome (included in the relevant chapter write-ups):&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Randomised studies: meta-analysed, where appropriate and reported in GRADE profiles (for clinical studies) &amp;ndash; see the full version of the original guideline document for details &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Observational studies: each study summarised in a table and narrative developed &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Qualitative studies: each study summarised in a table and narrative developed &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Economic studies: summarised in NICE economic evidence profiles &amp;ndash; see the full version of the original guideline document for details. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Methods of Combining Clinical Studies&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Data Synthesis for Intervention Reviews&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Where possible, meta-analyses were conducted to combine the results of studies for each review question using Cochrane Review Manager (RevMan5) software. Fixed-effects (Mantel-Haenszel) techniques were used to calculate risk ratios (relative risk) for the binary outcomes: (death, cardiac death, myocardial infarction [MI]/non-fatal MI, revascularisation, stroke, number patients free of angina, adverse events). The continuous outcome(s) (exercise tolerance, angina frequency, nitroglycerin consumption) was (were) analysed using an inverse variance method for pooling weighted mean differences and where the studies had different scales, standardised mean differences were used.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Statistical heterogeneity was assessed by considering the chi-squared test for significance at p&amp;lt;0.05 or an I-squared inconsistency statistic of &amp;gt;50% to indicate significant heterogeneity. When there were a high number of studies, a p-value of 0.1 was taken as a threshold for heterogeneity. The Guideline Development Group (GDG) carried out predefined subgroup analyses as defined in the protocol for each question (see Appendix B in the full version of the original guideline document).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The standard deviations of continuous outcomes were required for imputation for meta-analysis. However, in cases where this was not reported, calculation based on methods outlined in section 7.7.3 of the Cochrane Handbook: 'Data extraction for continuous outcomes' were applied to estimate the standard deviations if p values of the difference between two means, 95% confidence intervals or standard error of the mean (SEM) had been reported'. Where p values were reported as 'less than', a conservative approach was undertaken. For example, if p value was reported as 'p&amp;le;0.001', the calculations for standard deviations will be based on a p value of 0.001. If these statistical measures were not available then the methods described in section 16.1.3 of the Cochrane Handbook (February 2008) 'Missing standard deviations' were applied as the last resort.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For binary outcomes, absolute event rates were also calculated using the GRADEpro software using event rate in the control arm of the pooled results.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In the evidence reviews in this guideline we have presented additional data from studies along with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tables. These have been referred to as 'Additional data' and refer to data which was not analysed due to lack of sufficient reported information and/or outcomes.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Data Synthesis for Prognostic Review&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Odds ratio, relative or hazard risks, with their 95% confidence intervals, from multivariate analyses were extracted from the papers. Studies were not combined in a meta-analysis for observational studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;GRADE (Grading of Recommendations Assessment, Development and Evaluation)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The evidence for outcomes from studies which passed the quality assessment were evaluated and presented using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group (&lt;a href=&quot;http://www.gradeworkinggroup.org/&quot; title=&quot;GRADE web site&quot;&gt;http://www.gradeworkinggroup.org/&lt;/a&gt;). The software (GRADEpro) developed by the GRADE working group was used to assess pooled outcome data using individual study quality assessments and results from meta-analysis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The summary of findings was presented as two separate tables in this guideline. The &quot;Clinical Study Characteristics&quot; table includes details of the quality assessment while the &quot;Clinical Summary of Findings&quot; table includes pooled outcome data, where appropriate, an absolute measure of intervention effect calculated and the summary of quality of evidence for that outcome. In this table, the columns for intervention and control indicate pooled sample size for continuous outcomes. For binary outcomes such as number of patients with an adverse event, the event rates (n/N) are shown with percentages. Reporting or publication bias was only taken into consideration in the quality assessment and included in the Clinical Study Characteristics table if it was apparent.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See the full version of the original guideline document for additional grading of quality elements.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC)&lt;/strong&gt;: This guideline was developed by the National Clinical Guideline Centre on behalf of the National Institute for Health and Clinical Excellence (NICE). See the &quot;Availability of Companion Documents&quot; field for the full version of this guidance.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A multidisciplinary Guideline Development Group (GDG) comprising professional group members and consumer representatives of the main stakeholders developed this guideline. The group met approximately every 6 weeks during the development of the guideline. Developers took into account both clinical and cost effectiveness when making recommendations involving a choice between alternative interventions. A review of the economic evidence was conducted and analyses were carried out as appropriate. The unit of effectiveness was the quality-adjusted life year (QALY), and the costs considered were from an National Health Service (NHS) and personal social services (PSS) perspective. Further detail on the methods can be found in 'The guidelines manual' (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Developing the Review Questions and Outcomes&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Review questions were developed based on the scope (see Appendix A in the full version of the original guideline document). They were drafted by the review team and refined and validated by the Guideline Development Group (GDG). Review questions were developed in a PICO framework (patient, intervention, comparison and outcome) for intervention reviews, risk scores and prognostic reviews. This was to guide the literature searching process and to facilitate the development of recommendations by the GDG.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cost-Effectiveness Criteria&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The NICE Guidelines Manual sets out the principles that GDGs should consider when judging whether an intervention offers good value for money. In general, an intervention was considered to be cost effective if either of the following criteria applied (given that the estimate was considered plausible):&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The intervention dominated other relevant strategies (that is, it was both less costly in terms of resource use and more clinically effective compared with all the other relevant alternative strategies), or &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The intervention cost less than &amp;pound;20,000 per QALY gained compared with the next best strategy &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Developing Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Over the course of the guideline development process, the GDG was presented with:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Evidence tables of the clinical and economic evidence reviewed from the literature. All evidence tables are in Appendix E2&amp;nbsp;in the full version of the guideline document &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Summary of clinical and economic evidence and quality (as presented in chapters 5&amp;ndash;19 in the full version of the guideline document) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Forest plots (Appendix F in the full version of the guideline document) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A description of the methods and results of the cost-effectiveness analysis undertaken for the guideline (Appendices G and H in the full version of the guideline document). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Recommendations were drafted on the basis of this evidence whenever it was available.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;When clinical and economic evidence was absent, of poor quality or conflicting, the GDG drafted recommendations based on their expert opinion. This was done through discussions in the GDG. The considerations for making these consensus based recommendations included the balance between potential harms and benefits, economic or clinical implications compared to the benefits, current practices, recommendations made in other relevant guidelines, patient preferences and equality issues. The GDG also considered whether the uncertainty was sufficient to justify delaying making a recommendation to await further research, taking into account the potential harm of failing to make a clear recommendation.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Economic Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Eleven studies were found that included the relevant comparison of coronary artery bypass&amp;nbsp;graft (CABG) or percutaneous coronary intervention (PCI) in people with stable coronary artery disease. These are summarised in the Economics Evidence Tables in Appendix G in the full version of the guideline document. However, none of the studies fully met the quality and applicability criteria. It was thus decided to build an original economic model to compare PCI and CABG, which is reported in the economic profile tables in the full version of the guideline document. The model was based on the outcomes included in the clinical review (death, myocardial infarction [MI], repeat revascularisation, angina symptoms) at different time points up to 10 years from the initial procedure. Costs considered were the initial costs associated with the procedure (PCI or CABG, including the cost of four stents in the PCI strategy), the cost of further revascularisations and further investigations, anti-anginal medications, and the cost of treating myocardial infarctions. Please see cost-effectiveness analysis in Appendix H in the full version of the guideline document for further details.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Medical treatment is more cost-effective than early revascularisation with either coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) in people with stable coronary artery disease including people with type 2 diabetes mellitus. However if symptoms are not controlled, revascularisation is effective and could be cost-effective.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The economic evidence regarding people with stable coronary artery disease has overall minor limitations but partial applicability. The economic evidence regarding people with type 2 diabetes and stable coronary artery disease has potentially serious limitations (unclear quality-adjusted life years [QALY] calculations) and partial applicability (United States of America [USA] study).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In people with multi-vessel disease who are suitable for both CABG and PCI, PCI is more cost-effective. This result was not significant and a probabilistic analysis showed a high uncertainty around the cost-effectiveness of PCI vs. CABG. PCI was the preferred strategy in 63% of the simulations and results were dependent on the type of repeat procedure (if CABG was the procedure in more than 85% of the cases, PCI was not cost-effective). In people with single vessel disease PCI is likely to be even more cost-effective.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;An original economic model showed that PCI is more cost-effective than CABG in people with multi-vessel disease eligible for both procedures. The model had a 10-year time horizon; the probabilities of clinical events at 6 months, 1 year, 2, 3, 5 and 10 years were obtained from the meta-analysis of the studies comparing PCI with stents to CABG included in the clinical review. In the model, patients in the CABG arm experienced overall fewer MI and repeat revascularisations compared to patients in the PCI arm; the incremental QALYs of CABG compared to PCI was 0.069. This small QALY gain does not justify the incremental cost of CABG compared to PCI (&amp;pound;2,427) as the incremental cost-effectiveness ratio is above &amp;pound;30,000/QALY. The higher cost of CABG is due to the higher initial cost of the procedure (&amp;pound;8,552 vs. &amp;pound;4,839 with PCI). There is however some uncertainty around this conclusion and some applicability issues (the population enrolled in the trials on which the model is based might not be representative of the wider population of patients with angina). Variation in patients' preference for one procedure or the other could play a decisive role when establishing the most cost-effective procedure. Therefore, patient preference should be assessed when discussing the revascularisation strategy.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline was validated through two consultations.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The first draft of the guideline (the full guideline, National Institute for Health and Clinical Excellence [NICE] guideline, and Quick Reference Guide) were consulted with Stakeholders and comments were considered by the Guideline Development Group (GDG) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The final consultation draft of the full guideline, the NICE guideline and the Information for the Public were submitted to stakeholders for final comments. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;The final draft was submitted to the Guideline Review Panel for review prior to publication.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC)&lt;/strong&gt;: This guideline was developed by the National Clinical Guideline Centre on behalf of the National Institute for Health and Clinical Excellence (NICE). See the &quot;Availability of Companion Documents&quot; field for the full version of this guidance.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Diagnosis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Diagnose stable angina according to 'Chest pain of recent onset' (see the NGC summary of the NICE guideline &lt;a href=&quot;/content.aspx?id=16392&quot; title=&quot;Guideline #7980&quot;&gt;Chest pain of recent onset&lt;/a&gt;). Diagnose and manage unstable angina and non-ST-segment-elevation myocardial infarction (NSTEMI) according to 'Chest pain of recent onset' (see the NGC summary of the NICE guideline &lt;a href=&quot;/content.aspx?id=16392&quot; title=&quot;Guideline #7980&quot;&gt;Chest pain of recent onset&lt;/a&gt;), 'Unstable angina and NSTEMI' (see the NGC summary of the NICE clinical guideline &lt;a href=&quot;/content.aspx?id=16393&quot; title=&quot;Guideline #7891&quot;&gt;Unstable angina and NSTEMI&lt;/a&gt;) and 'MI: secondary prevention' (see the NICE guideline &lt;a href=&quot;http://guidance.nice.org.uk/CG48&quot; title=&quot;NICE Web site&quot;&gt;Post myocardial infarction&lt;/a&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Information and Support for People with Stable Angina&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Clearly explain stable angina to the person, including factors that can provoke angina (for example, exertion, emotional stress, exposure to cold, eating a heavy meal) and its long-term course and management. When relevant, involve the person's family or carers in the discussion.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Encourage the person with stable angina to ask questions about their angina and its treatment. Provide opportunities for them to voice their concerns and fears.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Discuss the person's, and if appropriate, their family or carer's ideas, concerns and expectations about their condition, prognosis and treatment. Explore and address any misconceptions about stable angina and its implications for daily activities, heart attack risk and life expectancy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Advise the person with stable angina to seek professional help if there is a sudden worsening in the frequency or severity of their angina.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Discuss with the person the purpose and any risks and benefits of their treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Assess the person's need for lifestyle advice (for example about exercise, stopping smoking, diet and weight control) and psychological support, and offer interventions as necessary.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Explore and address issues according to the person's needs, which may include:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Self-management skills such as pacing their activities and goal setting &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Concerns about the impact of stress, anxiety or depression on angina &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Advice about physical exertion including sexual activity &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;General Principles for Treating People with Stable Angina&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Do not exclude people with stable angina from treatment based on their age alone.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Do not investigate or treat symptoms of stable angina differently in men and women or in different ethnic groups.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Preventing and Treating Episodes of Angina&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Offer a short-acting nitrate for preventing and treating episodes of angina. Advise people with stable angina:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;How to administer the short-acting nitrate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To use it immediately before any planned exercise or exertion &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;That side effects such as flushing, headache and lightheadedness may occur &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To sit down or find something to hold on to if feeling light-headed &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;When a short-acting nitrate is being used to treat episodes of angina, advise people:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To repeat the dose after 5 minutes if the pain has not gone &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To call an emergency ambulance if the pain has not gone 5 minutes after taking a second dose &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Drugs for Secondary Prevention of Cardiovascular Disease&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Consider aspirin 75 mg daily for people with stable angina, taking into account the risk of bleeding and comorbidities.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Consider angiotensin-converting enzyme (ACE) inhibitors for people with stable angina and diabetes. Offer or continue ACE inhibitors for other conditions, in line with relevant NICE guidance.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Offer statin treatment in line with &lt;a href=&quot;http://guidance.nice.org.uk/CG67&quot; title=&quot;NICE Web site&quot;&gt;Lipid modification&lt;/a&gt; (NICE clinical guideline 67).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Offer treatment for high blood pressure in line with 'Hypertension' (see the NGC summary of the NICE guideline &lt;a href=&quot;/content.aspx?id=34824&quot; title=&quot;Guideline #8751&quot;&gt;Hypertension. Clinical management of primary hypertension in adults&lt;/a&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Dietary Supplements&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Do not offer vitamin or fish oil supplements to treat stable angina. Inform people that there is no evidence that they help stable angina.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Anti-anginal Drug Treatment&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;General Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Offer people optimal drug treatment for the initial management of stable angina. Optimal drug treatment consists of one or two anti-anginal drugs as necessary plus drugs for secondary prevention of cardiovascular disease.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Advise people that the aim of anti-anginal drug treatment is to prevent episodes of angina and the aim of secondary prevention treatment is to prevent cardiovascular events such as heart attack and stroke.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Discuss how side effects of drug treatment might affect the person's daily activities and explain why it is important to take drug treatment regularly.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients differ in the type and amount of information they need and want. Therefore the provision of information should be individualised and is likely to include, but not be limited to:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;What the medicine is &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;How the medicine is likely to affect their condition (that is, its benefits) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Likely or significant adverse effects and what to do if they think they are experiencing them &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;How to use the medicine &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;What to do if they miss a dose &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Whether further courses of the medicine will be needed after the first prescription &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;How to get further supplies of medicines. (This recommendation is from 'Medicines adherence' [see the NICE guideline &lt;a href=&quot;http://www.nice.org.uk/guidance/CG76&quot; title=&quot;NICE Web site&quot;&gt;Medicines adherence. Involving patients in decisions about prescribed medicines and supporting adherence&lt;/a&gt;].) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Review the person's response to treatment, including any side effects, 2&amp;ndash;4 weeks after starting or changing drug treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Titrate the drug dosage against the person's symptoms up to the maximum tolerable dosage.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Drugs for Treating Stable Angina&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Offer either a beta blocker or a calcium channel blocker as first-line treatment for stable angina. Decide which drug to use based on comorbidities, contraindications and the person's preference.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If the person cannot tolerate the beta blocker or a calcium channel blocker, consider switching to the other option (calcium channel blocker or beta blocker).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If the person's symptoms are not satisfactorily controlled on a beta blocker or a calcium channel blocker, consider either switching to the other option or using a combination of the two.*&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*When combining a calcium channel blocker with a beta blocker, use a dihydropyridine calcium channel blocker, for example, slow release nifedipine, amlodipine or felodipine.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Do not routinely offer anti-anginal drugs other than beta blockers or calcium channel blockers as first-line treatment for stable angina.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If the person cannot tolerate beta blockers and calcium channel blockers or both are contraindicated, consider monotherapy with one of the following drugs:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A long-acting nitrate &lt;strong&gt;or&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ivabradine &lt;strong&gt;or&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nicorandil &lt;strong&gt;or&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ranolazine &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Decide which drug to use based on comorbidities, contraindications, the person's preference and drug costs.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For people on beta blocker or calcium channel blocker monotherapy whose symptoms are not controlled and the other option (calcium channel blocker or beta blocker) is contraindicated or not tolerated, consider one of the following as an additional drug:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A long-acting nitrate &lt;strong&gt;or&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ivabradine* &lt;strong&gt;or&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nicorandil** &lt;strong&gt;or&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ranolazine &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*When combining ivabradine with a calcium channel blocker, use a dihydropyridine calcium channel blocker, for example, slow release nifedipine, amlodipine, or felodipine.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;**At the time of publication (July 2011), nicorandil did not have UK marketing authorisation for this indication. Informed consent should be obtained and documented.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Decide which drug to use based on comorbidities, contraindications, the person's preference and drug costs.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Do not offer a third anti-anginal drug to people whose stable angina is controlled with two anti-anginal drugs.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Consider adding a third anti-anginal drug only when:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The person's symptoms are not satisfactorily controlled with two anti-anginal drugs &lt;strong&gt;and&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The person is waiting for revascularisation or revascularisation is not considered appropriate or acceptable &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Decide which drug to use based on comorbidities, contraindications, the person's preference and drug costs.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Investigation and Revascularisation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;People with Stable Angina Whose Symptoms Are Not Satisfactorily Controlled with Optimal Medical Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Consider revascularisation (coronary artery bypass graft [CABG] or percutaneous coronary intervention [PCI]) for people with stable angina whose symptoms are not satisfactorily controlled with optimal medical treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Offer coronary angiography to guide treatment strategy for people with stable angina whose symptoms are not satisfactorily controlled with optimal medical treatment. Additional non-invasive or invasive functional testing may be required to evaluate angiographic findings and guide treatment decisions. (This recommendation partially updates recommendation 1.2 of 'Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction' [see the NICE Web site for &lt;a href=&quot;http://www.nice.org.uk/TA73&quot; title=&quot;NICE Web site&quot;&gt;Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction&lt;/a&gt;].)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Offer CABG to people with stable angina and suitable coronary anatomy when:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Their symptoms are not satisfactorily controlled with optimal medical treatment &lt;strong&gt;and&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Revascularisation is considered appropriate &lt;strong&gt;and&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;PCI is not appropriate &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Offer PCI to people with stable angina and suitable coronary anatomy when:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Their symptoms are not satisfactorily controlled with optimal medical treatment &lt;strong&gt;and&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Revascularisation is considered appropriate &lt;strong&gt;and&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CABG is not appropriate &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;When either procedure would be appropriate, explain to the person the risks and benefits of PCI and CABG for people with anatomically less complex disease whose symptoms are not satisfactorily controlled with optimal medical treatment. If the person does not express a preference, take account of the evidence that suggests that PCI may be the more cost-effective procedure in selecting the course of treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;When either procedure would be appropriate, take into account the potential survival advantage of CABG over PCI for people with multivessel disease whose symptoms are not satisfactorily controlled with optimal medical treatment and who:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Have diabetes &lt;strong&gt;or&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Are over 65 years &lt;strong&gt;or&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Have anatomically complex three-vessel disease, with or without involvement of the left main stem &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Consider the relative risks and benefits of CABG and PCI for people with stable angina using a systematic approach to assess the severity and complexity of the person's coronary disease, in addition to other relevant clinical factors and comorbidities.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Ensure that there is a regular multidisciplinary team meeting to discuss the risks and benefits of continuing drug treatment or revascularisation strategy (CABG or PCI) for people with stable angina. The team should include cardiac surgeons and interventional cardiologists. Treatment strategy should be discussed for the following people, including but not limited to:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;People with left main stem or anatomically complex three-vessel disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;People in whom there is doubt about the best method of revascularisation because of the complexity of the coronary anatomy, the extent of stenting required or other relevant clinical factors and comorbidities. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Ensure people with stable angina receive balanced information and have the opportunity to discuss the benefits, limitations and risks of continuing drug treatment, CABG and PCI to help them make an informed decision about their treatment. When either revascularisation procedure is appropriate, explain to the person:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The main purpose of revascularisation is to improve the symptoms of stable angina. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CABG and PCI are effective in relieving symptoms. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Repeat revascularisation may be necessary after either CABG or PCI and the rate is lower after CABG. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stroke is uncommon after either CABG or PCI, and the incidence is similar between the two procedures. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is a potential survival advantage with CABG for some people with multivessel disease. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Inform the person about the practical aspects of CABG and PCI. Include information about:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Vein and/or artery harvesting &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Likely length of hospital stay &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recovery time &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Drug treatment after the procedure &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;People with Stable Angina Whose Symptoms Are Satisfactorily Controlled with Optimal Medical Treatment &lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Discuss the following with people whose symptoms are satisfactorily controlled with optimal medical treatment:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Their prognosis without further investigation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The likelihood of having left main stem disease or proximal three-vessel disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The availability of CABG to improve the prognosis in a subgroup of people with left main stem or proximal three-vessel disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The process and risks of investigation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The benefits and risks of CABG, including the potential survival gain &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;After discussion (see above) with people whose symptoms are satisfactorily controlled with optimal medical treatment, consider a functional or non-invasive anatomical test to identify people who might gain a survival benefit from surgery. Functional or anatomical test results may already be available from diagnostic assessment. (This recommendation partially updates recommendation 1.2 of 'Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction' [see the NICE Web site for &lt;a href=&quot;http://www.nice.org.uk/TA73&quot; title=&quot;NICE Web site&quot;&gt;Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction&lt;/a&gt;].)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;After discussion (see above) with people whose symptoms are satisfactorily controlled with optimal medical treatment, consider coronary angiography when:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Functional testing indicates extensive ischaemia or non-invasive anatomical testing indicates the likelihood of left main stem or proximal three-vessel disease &lt;strong&gt;and&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Revascularisation is acceptable and appropriate &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Consider CABG for people with stable angina and suitable coronary anatomy whose symptoms are satisfactorily controlled with optimal medical treatment, but coronary angiography indicates left main stem disease or proximal three-vessel disease.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Pain Interventions&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Do not offer the following interventions to manage stable angina:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Transcutaneous electrical nerve stimulation (TENS) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Enhanced external counterpulsation (EECP) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acupuncture &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Stable Angina That Has Not Responded to Treatment&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Offer people whose stable angina has not responded to drug treatment and/or revascularisation comprehensive re-evaluation and advice, which may include:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Exploring the person's understanding of their condition &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exploring the impact of symptoms on the person's quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reviewing the diagnosis and considering non-ischaemic causes of pain &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reviewing drug treatment and considering future drug treatment and revascularisation options &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acknowledging the limitations of future treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Explaining how the person can manage the pain themselves &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Specific attention to the role of psychological factors in pain &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Development of skills to modify cognitions and behaviours associated with pain &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Cardiac Syndrome X&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In people with angiographically normal coronary arteries and continuing anginal symptoms, consider a diagnosis of cardiac syndrome X.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Continue drug treatment for stable angina only if it improves the symptoms of the person with suspected cardiac syndrome X.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Do not routinely offer drugs for the secondary prevention of cardiovascular disease to people with suspected cardiac syndrome X.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A care pathway on the management of stable angina is available in the Quick Reference Guide (see &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of evidence supporting the recommendations is not specifically stated.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Appropriate care of people with stable angina &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prevention of secondary cardiac disease &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of short-acting nitrates include flushing, headache, and light-headedness. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Side effects of other medications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Complications of surgery &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;This guidance represents the view of National Institute of Health and Clinical Excellence (NICE), which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, and informed by the summary of product characteristics of any drugs they are considering. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Key Priorities for Implementation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The following recommendations have been identified as priorities for implementation.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Explore and address issues according to the person's needs, which may include:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Self-management skills such as pacing their activities and goal setting &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Concerns about the impact of stress, anxiety or depression on angina &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Advice about physical exertion including sexual activity &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Offer people optimal drug treatment for the initial management of stable angina. Optimal drug treatment consists of one or two anti-anginal drugs as necessary plus drugs for secondary prevention of cardiovascular disease. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider revascularisation (coronary artery bypass graft [CABG] or percutaneous coronary intervention [PCI]) for people with stable angina whose symptoms are not satisfactorily controlled with optimal medical treatment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When either procedure would be appropriate, explain to the person the risks and benefits of PCI and CABG for people with anatomically less complex disease whose symptoms are not satisfactorily controlled with optimal medical treatment. If the person does not express a preference, take account of the evidence that suggests that PCI may be the more cost-effective procedure in selecting the course of treatment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When either procedure would be appropriate, take into account the potential survival advantage of CABG over PCI for people with multivessel disease whose symptoms are not satisfactorily controlled with optimal medical treatment and who:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Have diabetes &lt;strong&gt;or&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Are over 65 years &lt;strong&gt;or&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Have anatomically complex three-vessel disease, with or without involvement of the left main stem &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider the relative risks and benefits of CABG and PCI for people with stable angina using a systematic approach to assess the severity and complexity of the person's coronary disease, in addition to other relevant clinical factors and comorbidities. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ensure that there is a regular multidisciplinary team meeting to discuss the risks and benefits of continuing drug treatment or the revascularisation strategy (CABG or PCI) for people with stable angina. The team should include cardiac surgeons and interventional cardiologists. Treatment strategy should be discussed for the following people, including but not limited to:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;People with left main stem or anatomically complex three-vessel disease &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;People in whom there is doubt about the best method of revascularisation because of the complexity of coronary anatomy, the extent of stenting required or other relevant clinical factors and comorbidities &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ensure people with stable angina receive balanced information and have the opportunity to discuss the benefits, limitations and risks of continuing drug treatment, CABG and PCI to help them make an informed decision about their treatment. When either revascularisation procedure is appropriate, explain to the person:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The main purpose of revascularisation is to improve the symptoms of stable angina. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;CABG and PCI are effective in relieving symptoms. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Repeat revascularisation may be necessary after either CABG or PCI and the rate is lower after CABG. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Stroke is uncommon after either CABG or PCI, and the incidence is similar between the two procedures. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;There is a potential survival advantage with CABG for some people with multivessel disease. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Discuss the following with people whose symptoms are satisfactorily controlled with optimal medical treatment:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Their prognosis without further investigation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The likelihood of having left main stem disease or proximal three-vessel disease &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The availability of CABG to improve the prognosis in a subgroup of people with left main stem or proximal three-vessel disease &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The process and risks of investigation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The benefits and risks of CABG, including the potential survival gain. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Audit Criteria/Indicators" /><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Foreign Language Translations" /><FieldValue Value="Patient Resources" /><FieldValue Value="Quick Reference Guides/Physician Guides" /><FieldValue Value="Resources" /><FieldValue Value="Slide Presentation" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Clinical Guideline Centre. Management of stable angina. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Jul. 34 p.&amp;nbsp;(Clinical guideline; no. 126).&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2011 Jul" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="National Clinical Guideline Centre - National Government Agency [Non-U.S.]" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;National Institute for Health and Clinical Excellence (NICE)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Guideline Development Group&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Guideline Development Group (GDG) Members&lt;/em&gt;: Adam Timmis (&lt;em&gt;Chair&lt;/em&gt;), Professor of Clinical Cardiology, Barts and the London Queen Mary's School of Medicine and Dentistry; Robert Henderson (&lt;em&gt;Clinical Adviser&lt;/em&gt;), Consultant Cardiologist, Trent Cardiac Centre, Nottingham University Hospitals; Sotiris Antoniou, Consultant Pharmacist for Cardiovascular Medicine, Barts and The London NHS Trust and North East London Cardiovascular and Stroke Network; Christopher Blauth, Consultant Surgeon, Cardiac Centre, St Thomas's Hospital, London; Liz Clark, Patient and carer member; Kevin Fox, Consultant Cardiologist, Department of Cardiology, Charing Cross Hospital, London; Leonard Jacob, GPSI in Cardiology and GP CVD Lead, NHS Rotherham; Aidan MacDermott, Cardiovascular Clinical Team Leader, County Durham and Darlington PCT; Helen O'Leary, Angina Clinical Nurse Specialist, Nevil Hall Hospital, Abergavenny, Monmouthshire; Charles Peebles, Consultant Cardiac Radiologist, Department of Cardiothoracic Radiology, Southampton General Hospital; Maurice Pye, Consultant Cardiologist, York Hospital; Jonathan Shribman, General Practitioner and GPSI in Cardiology, Bugbrooke Medical Practice, Bugbrooke, Northants; Roger Till, Patient and carer member&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;At the start of the guideline development process all GDG members all members of the NCGC staff declared interests including consultancies, fee-paid work, share-holdings, fellowships and support from the healthcare industry. At all subsequent GDG meetings, members declared arising conflicts of interest, which were also recorded. Members were either required to withdraw completely or for part of the discussion if their declared interest made it appropriate.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;No interests were declared that required actions. The details of declared interests are shown in Appendix J of the full version of the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.nice.org.uk/guidance/CG126&quot; title=&quot;NICE Web site&quot;&gt;National Institute for Health and Clinical Excellence (NICE) Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Stable angina. Quick reference guide. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Jul. 13 p. (Clinical guideline; no. 126). Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://guidance.nice.org.uk/CG126/QuickRefGuide/pdf/English&quot; title=&quot;NICE Web site&quot;&gt;National Institute for Health and Clinical Excellence (NICE) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stable angina. Full guideline. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Jul. 468 p. (Clinical guideline; no. 126). Electronic copies: Available in PDF from the &lt;a href=&quot;http://guidance.nice.org.uk/CG126/Guidance/pdf/English &quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stable angina. Appendices. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Jul. Various p. (Clinical guideline; no. 126). Electronic copies: Available in PDF from the &lt;a href=&quot;http://guidance.nice.org.uk/CG126/Guidance/Appendices&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stable angina. Clinical audit tool. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Jul. Various p. (Clinical guideline; no. 126). Electronic copies: Available from the &lt;a href=&quot;http://guidance.nice.org.uk/CG126/ClinicalAudit/doc/English&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stable angina. Costing statement. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Jul. 6 p. (Clinical guideline; no. 126). Electronic copies: Available in PDF from the &lt;a href=&quot;http://guidance.nice.org.uk/CG126/CostingStatement/pdf/English&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stable angina. Slide set. Implementing NICE guidance. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Jul. 22 p. (Clinical guideline; no. 126). Electronic copies: Available from the &lt;a href=&quot;http://guidance.nice.org.uk/CG126/SlideSet/ppt/English&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stable angina. Baseline assessment tool. Implementing NICE guidance. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011. (Clinical guideline; no. 126). Electronic copies: Available from the &lt;a href=&quot;http://guidance.nice.org.uk/CG126/BaselineAssessment/xls/English&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Factsheet on revascularisation for stable angina.&amp;nbsp;London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Jul. 31 p. (Clinical guideline; no. 126). Electronic copies: Available in PDF from the &lt;a href=&quot;http://guidance.nice.org.uk/CG126/Factsheet/pdf/English&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The guidelines manual 2009. London (UK): National Institute for Health and Clinical Excellence (NICE); 2009 Jan. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.nice.org.uk/aboutnice/howwework/developingniceclinicalguidelines/clinicalguidelinedevelopmentmethods/GuidelinesManual2009.jsp&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Additional educational resources are available from the &lt;a href=&quot;http://guidance.nice.org.uk/CG126/EducationResource&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Stable angina. Understanding NICE guidance. Information for people who use NHS services. London (UK): National Institute for Health and Clinical Excellence; 2011 Jul. 12 p. (Clinical guideline; no. 126). Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://guidance.nice.org.uk/CG126/PublicInfo/pdf/English&quot; title=&quot;NICE Web site&quot;&gt;National Institute for Health and Clinical Excellence (NICE) Web site&lt;/a&gt;. Also available in Welsh from the &lt;a href=&quot;http://guidance.nice.org.uk/CG126/PublicInfo/doc/Welsh&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on February 24, 2012. This summary was updated by ECRI Institute on April 13, 2012 following the U.S. Food and Drug Administration advisories on Statin Drugs and Statins and HIV or Hepatitis C drugs.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The National Institute for Health and Clinical Excellence (NICE) has granted the National Guideline Clearinghouse (NGC) permission to include summaries of their clinical guidelines with the intention of disseminating and facilitating the implementation of that guidance. NICE has not yet verified this content to confirm that it accurately reflects that original NICE guidance and therefore no guarantees are given by NICE in this regard. All NICE clinical guidelines are prepared in relation to the National Health Service in England and Wales. NICE has not been involved in the development or adaptation of NICE guidance for use in any other country. The full versions of all NICE guidance can be found at &lt;a href=&quot;http://www.nice.org.uk&quot; title=&quot;NICE Web site&quot;&gt;www.nice.org.uk&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
